摘要
目的观察对比不同剂量阿托伐他汀治疗心肌梗死合并心衰患者的临床效果。方法选取我院2009年5月至2011年5月42例心肌梗死合并心衰的患者，均行经皮冠状动脉介入术（PCI），随机分为观察组和对照组，各21例。观察组患者术前口服40mg／d阿托伐他汀；对照组患者术前口服20mg／d阿托伐他汀，观察比较两组患者入院前24h、术前1d、术后1d、术后3d、术后4周血清高敏C-反应蛋白（hs—CRP）的变化。结果两组术后3d血清hs—CRP与入院前24h、术前1d相比差异有统计学意义（P〈0．05）；两组术后3dhs—CRP比较差异有统计学意义（P〈0．05）。结论心肌梗死合并心衰患者在行PCI术前给予口服40mg／d阿托伐他汀治疗，能有效降低血清中的炎症因子，增高血清中的炎症保护因子，从而保护心功能。
Objective To observe the effects of different doses of atorvastatin in the treatment of myocardial infarction complicated with heart failure. Methods From May 2009 to May 2011, 42 cases of patients with myocardial infarction complicated by heart failure underwent percutaneous coronary intervention（PCI） in our hospital were enrolled. The patients were randomly divided into observation group（n=21 ） and the control group（n=21 ）. The observation group took 40 mg/d of atorvastatin preoperation, and the control group took 20 mg/d of atorvastatin preoperation. Serum levels of high-sensitivity C-reactive protein（hs-CRP） in two groups were measured after admission 24 h, preoperative 1 d, 3 d and 4 weeks postoperation. Results The serum level of hs-CRP in 3 d postoperative was significantly higher than admission and 1 d preoperation （P〈0.05） in two groups. The level of hs-CRP postoperative 3 d was significantly different between two groups （P〈0.05）. Conclusion Taken 40 mg/d of atorvastatin pre-PCI in patients with myocardial infarction complicated with heart failure can effectively reduce serum inflammatory cytokines.
出处
《中国心血管病研究》
CAS
2012年第3期203-205,共3页
Chinese Journal of Cardiovascular Research
关键词
阿托伐他汀
心肌梗死
心力衰竭
经皮冠状动脉介入术
Atorvastatin
Myocardial infarction
Heart failure
Percutaneous coronary intervention
